<i>In vivo</i>Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor

S. van der Heijden, Michiel; R. Brody, Jonathan; A. Dezentjé, David; Gallmeier, Eike; C. Cunningham, Steven; J. Swartz, Michael; M. De Marzo, Angelo; Johan A. Offerhaus, G.; H. Isacoff, William; H. Hruban, Ralph; E. Kern, Scott

doi:10.1158/1078-0432.ccr-05-1048

Public

In vivoTherapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor

Published in Clinical Cancer Research • Oct 15, 2005

Authors:

Michiel S. van der Heijden

Jonathan R. Brody

David A. Dezentjé

Abstract

PURPOSE: BRCA2, FANCC, and FANCG gene mutations are present in a subset of pancreatic cancer. Defects in these genes could lead to hypersensitivity to interstrand cross-linkers in vivo and a more optimal treatment of pancreatic cancer patients based on the genetic profile of the tumor. EXPERIMENTAL ...

Subject

Fanconi anemia

Cancer research

Gemcitabine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!